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Targeting a Heterogeneous
Tumor: The Promise of
the Interleukin-13
Receptor a2
M olecular and histological heterogene-ity presents a major challenge in theeffective treatment of glioblastoma
(GBM). Despite this tumor heterogeneity, there
is a promise of a therapeutic target in an antigen
that is selectively expressed in glioma compared
with normal brain tissue, the interleukin-13
(IL-13) receptor a2 (IL-13Ra2). This receptor
has been shown to bind with high affinity to
IL-13 and to downregulate the expression of its
usual receptor, the IL-13Ra1/IL-4Ra complex,
to mediate transforming growth factor b pro-
duction in tumor infiltrating monocytes and
macrophages, and to promote tumor infiltration
and proliferation. Notably, IL-13Ra2 expression
has also been identified in stem-like malignant
glioma cells. These selective expression patterns
in glioma compel further investigation into
therapeutic potential.
Further recognition of the exploitability of
IL-13Ra2 as a therapeutic target comes through
the work of Brown and colleagues.1 They used
a bioinformatics approach to characterize IL-
13Ra2 expression across 8 large, publicly
available gene expression profile data sets.
Principal component analysis was used to
determine the correlation between IL-13Ra2
expression and genes defining the molecular
subtypes of GBM presented by Phillips et al2
and Verhaak et al.3 Cell surface markers of these
molecular subtypes of glioma on IL-13Ra2–
expressing vs –nonexpressing low-passage pri-
mary glioma cell lines were determined by flow
cytometry, and gene expression profiles were
established. The functional consequences of the
resulting gene expression correlations were
probed through ingenuity pathway analysis.
Finally, they determined the survival signifi-
cance of these expression profiles.
The authors found a significantly higher level
of IL-13Ra2 expression in high-grade glioma
compared with low-grade glioma (P ¼ 2.4 ·
1024), with World Health Organization grade
IV gliomas having a 2.5-fold increase in
IL-13Ra2 expression level compared with grade
III gliomas (P ¼ 2.9 · 1028). This strong
association with glioma grade was independent of
molecular subtype or recurrence. By modeling
the bimodal expression of IL-13Ra2 seen in
GBM as the sum of 2 normal distributions, the
authors estimated a 58% IL-13Ra2 overexpres-
sion frequency in GBM. Importantly, principal
component analysis revealed that IL-13Ra2
expression was closely associated with mesen-
chymal gene expression according to the sub-
types defined by both Phillips et al2 and Verhaak
et al3 that were independently defined in these 2
studies by patient survival and unsupervised
clustering, respectively. Additionally, IL-13Ra2
expression correlates well with the expression
profile for the proliferative subtype defined by
Phillips et al.2 Its expression is inconsistently
correlated with the neural and classic subtypes
defined by Verhaak et al.3 These findings
corroborate with flow cytometry data from
patient-derived IL-13Ra2–positive glioma cell
lines showing greater expression of mesenchymal
adhesion markers such as CD44 and CD54/
intercellular adhesion molecule-1 compared with
IL-13Ra2–negative glioma cell lines.
The study further explores the functional and
survival implications of IL-13Ra2 overexpres-
sion. Ingenuity pathway analysis for high IL-
13Ra2 expression suggests the functional
involvement of canonical pathways associated
with mesenchymal genes and with immune-
related pathways. Not surprisingly, mesenchymal
gene signatures showed significant overlap with
immune pathways. The survival analyses of
GBM patients expressing high vs low
levels of IL-13Ra2 showed decreased patient
survival of 2.5 months with IL-13Ra2 over-
expression (P ¼ .00012; Figure). Median survival
for patients with high IL-13Ra2 expression was
13.1 months compared with 15.6 months (95%
confidence interval, 13.6-18.6; n ¼ 357) for
patients with low IL-13Ra2 expression, demon-
strating the role of IL-13Ra2 as a prognostic
marker of poor patient survival.
Figure. Overexpression of interleukin-13 receptor a2 (IL-13Ra2) is associated with decreased patient survival. A, Kaplan-Meier
survival plot for patients with glioblastoma segregated based on “‘high” vs “low” IL13Ra2 expression as determined with
nonlinear least-squares regression (Table 1 in File S1 in the article by Brown and colleagues1). Kaplan-Meier plots for the same
patient cohort evaluated in A are segregated on the basis of (B) mesenchymal (MES) signature gene expression or (C) proneural
(PN) signature gene expression, with “high” and “low” expression determined by median expression level.
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These findings add molecular associations,
functional implications, and prognostic value to
the known selective expression of IL-13Ra2 in
GBM tissue. The presence of this antigen on
GBM tissue serves as an important target for both
immune- and cytotoxic-based therapies. Immune
system activation has been implicated in the
resistance-promoting, epithelial-to-mesenchymal
transition. The high degree of correlation
between IL-13Ra2 and signature mesenchy-
mal genes may be used to target the most
resistant tumors. The predominant expression
of this receptor in GBM and its association
with poor patient prognosis present a promis-
ing opportunity for exploring the therapeutic
potential of downstream signaling pathways
and direct antigen targeting.
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S pinal cord injury is a devastating conditionthat greatly affects patients, their supportsystem, and the entire healthcare system.
The total economic burden to healthcare systems
approaches $10 billion annually and stems from
Figure. Restoration of muscle function in a controlled manner through the use of optical stimulation of engrafted channelrhodopsin-2 (ChR2) motor neurons in vivo.1 A, schematic of
optical stimulation and isometric muscle tension recordings setup. Representative twitch (B), tetanic (C), and repetitive tetanic (D) contraction traces obtained from the transversus
abdominis muscle, induced by optical stimulation. Blue shows muscle force; red, light-emitting diode (LED) light triggers. E, quantification of twitch and tetanic contraction of
transversus abdominis and extensor digitorum longus muscles. Time to peak contractile force, from initiation of the electrical trigger to the LED unit (F) or from the initiation of muscle
contraction (G), is shown alongside direct electric nerve stimulation.H, representative fatigue traces from transversus abdominis muscles produced by optical (top) or electrical (bottom)
stimulation for 180 seconds. I, representative transversus abdominis muscle optical stimulation motor-unit number estimate trace. The asterisk indicates square-wave trigger voltage to
the LED unit and oscilloscope trigger. J, motor-unit number quantification of transversus abdominis and extensor digitorum longus muscles after optical versus electrical stimulation.
K, analysis of average motor-unit force. The dashed line indicates the normal extensor digitorum longus value. All error bars indicate SEM. Reprinted with permission from Bryson JB,
Machado CB, Crossley M, et al. Optical control of muscle function by transplantation of stem-cell derived motor neurons in mice. Science. 2014;344(6179):94-97.
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